# Lecture 3: Gastrointestinal Secretion ## Unit 2.2: Gastrointestinal System --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the composition and regulation of salivary secretion 2. Explain gastric acid secretion and its regulation 3. Describe the phases of gastric secretion 4. Explain pancreatic exocrine secretion and its regulation 5. Describe bile secretion and the enterohepatic circulation 6. Explain intestinal secretion and its regulation --- ## Lecture Content ### Overview of GI Secretion The gastrointestinal tract secretes 7 to 9 liters of fluid daily to accomplish digestion and absorption. This remarkable volume comes from multiple specialized sources. Salivary glands contribute 1 to 1.5 liters, initiating digestion and providing lubrication. The stomach produces 2 to 3 liters of highly acidic secretion containing pepsin and intrinsic factor. The liver continuously produces 0.5 to 1 liter of bile, which the gallbladder concentrates and stores. The exocrine pancreas secretes 1 to 2 liters containing digestive enzymes and bicarbonate. The intestinal epithelium adds another 1 to 2 liters. Although most of this fluid is reabsorbed, the secretory capacity is essential for digestion. Regulation of GI secretion occurs at multiple levels. Neural control involves the autonomic nervous system: parasympathetic input (primarily vagal) generally stimulates secretion, while sympathetic input decreases secretion. Hormonal control involves peptide hormones released from enteroendocrine cells in response to luminal contents. Gastrin stimulates acid secretion. CCK stimulates pancreatic enzyme secretion and gallbladder contraction. Secretin stimulates pancreatic bicarbonate secretion. Paracrine mediators act locally: histamine potentiates acid secretion, while somatostatin inhibits it. Panel A: GI tract from mouth to colon with arrows pointing to secretory organs shown centrally. Panel B: Daily volumes as bar chart showing saliva 1-1.5 L, gastric 2-3 L, bile 0.5-1 L, pancreatic 1-2 L, intestinal 1-2 L totaling 7-9 L. Panel C: Regulatory mechanisms including neural with parasympathetic vagus nerve in green stimulating secretion and sympathetic in orange inhibiting. Panel D: Hormonal regulation showing gastrin, CCK, and secretin with target organs, and paracrine mediators histamine and somatostatin acting locally with arrows connecting each mechanism to appropriate organ targets. --- ### Salivary Secretion Three pairs of major salivary glands produce saliva with distinct compositions. The parotid glands produce purely serous (watery) secretion rich in amylase, contributing about 25% of saliva. The submandibular glands are mixed serous and mucous, contributing 70% of saliva—the largest proportion. The sublingual glands are predominantly mucous, contributing only about 5%. Numerous minor salivary glands in the oral mucosa produce additional mucus. Saliva composition supports multiple functions. Water provides lubrication for chewing and swallowing. Mucins (glycoproteins) coat food particles and oral tissues for protection. Alpha-amylase (ptyalin) begins starch digestion by cleaving α-1,4 glycosidic bonds. Lingual lipase initiates fat digestion, though its contribution is minor. Lysozyme has antibacterial properties. Secretory IgA provides immune defense. Bicarbonate buffers acids to protect enamel. Salivary secretion follows a two-stage model. In the first stage, acinar cells produce a primary secretion that is isotonic with plasma and contains amylase and mucins. In the second stage, as this fluid passes through the duct system, duct cells modify its electrolyte composition. Duct cells reabsorb sodium and chloride while secreting potassium and bicarbonate. Because the duct epithelium is relatively impermeable to water, water is not reabsorbed, resulting in hypotonic final saliva. Flow rate affects final composition. At low flow rates, duct cells have more time to reabsorb sodium and chloride, producing very hypotonic saliva with low sodium and relatively high potassium. At high flow rates (during active eating), less time for modification results in saliva that approaches isotonicity with higher sodium content. Both parasympathetic and sympathetic stimulation increase salivary secretion, though with different characteristics. Parasympathetic stimulation (via acetylcholine binding M3 receptors) dramatically increases volume and enzyme content—this is the dominant regulatory influence during eating. Sympathetic stimulation (via norepinephrine) produces a smaller volume of viscous, protein-rich saliva. Food in the mouth, through taste and mechanoreceptors, strongly stimulates salivation. Conditioned reflexes allow even the sight or smell of food to trigger salivation (as Pavlov famously demonstrated). Panel A: Anatomy of three major gland pairs with pie chart showing contributions with submandibular 70%, parotid 25%, and sublingual 5%. Panel B: Two-stage secretion model with acinar cells in purple producing isotonic primary secretion with amylase and mucins, and duct cells in blue modifying composition by reabsorbing Na+ and Cl- with arrows into cells and secreting K+ and HCO3- with arrows out of cells. Panel C: Final saliva composition comparison at low flow showing hypotonic with low Na+ and high K+ versus high flow showing less hypotonic with higher Na+. Panel D: Neural regulation with parasympathetic ACh and M3 receptor producing high volume watery secretion, and sympathetic NE producing low volume viscous secretion with ion transport diagrams. --- ### Gastric Acid Secretion The parietal cell is the acid-producing cell of the gastric mucosa, concentrated in the body and fundus. Its mechanism of acid secretion is one of the most energy-intensive cellular processes in the body, generating hydrochloric acid at a concentration of 150-160 mM (pH ≈ 1), a million-fold gradient across the apical membrane. The mechanism proceeds in several steps. Intracellular carbonic anhydrase catalyzes the combination of water and carbon dioxide to form carbonic acid, which dissociates into hydrogen ions and bicarbonate ions. The hydrogen ion is secreted into the gastric lumen via the H⁺/K⁺-ATPase (proton pump) on the apical membrane, exchanging hydrogen for potassium. This primary active transport consumes ATP directly. The potassium is recycled back to the lumen through apical potassium channels, making it available for continued exchange. Chloride ions follow through apical chloride channels, resulting in hydrochloric acid secretion. The bicarbonate ions exit across the basolateral membrane via a chloride/bicarbonate exchanger, entering the blood. This creates the "alkaline tide"—the transient rise in blood pH that occurs during active acid secretion after a meal. Three stimulants act on the parietal cell, and their interaction demonstrates the principle of potentiation. Acetylcholine (from vagal nerve endings) binds M3 muscarinic receptors, activating phospholipase C, increasing intracellular calcium, and promoting pump activity. Gastrin (from antral G cells) binds CCK-B receptors on parietal cells, also increasing calcium. Histamine (from neighboring enterochromaffin-like [ECL] cells) binds H2 receptors, increasing cyclic AMP. These three pathways potentiate each other—the combined effect is much greater than the sum of individual effects. This potentiation explains why blocking just one pathway (such as with H2 blockers) significantly reduces total acid output even though two other stimulants remain active. Inhibitors of acid secretion include somatostatin (from D cells, which inhibits both G cells and parietal cells), prostaglandins (which decrease cAMP in parietal cells), and secretin and GIP from the duodenum (which inhibit gastrin release). Panel A: Parietal cell with elaborate apical canaliculi showing acid secretion mechanism step by step with CO2 + H2O becoming H2CO3 becoming H+ + HCO3- with carbonic anhydrase labeled. Panel B: Apical membrane showing H+/K+-ATPase proton pump secreting H+ while taking in K+, K+ channels recycling K+ back to lumen, and Cl- channels secreting Cl-, with basolateral membrane showing Cl-/HCO3- exchanger releasing HCO3- labeled as alkaline tide. Panel C: Three receptor pathways shown on basolateral membrane with M3 from ACh via vagus increasing Ca2+, CCK-B from gastrin via G cell increasing Ca2+, and H2 from histamine via ECL cell increasing cAMP. Panel D: Potentiation diagram showing all three pathways converging to activate the proton pump with combined effect much greater than sum of individual effects in professional biochemical illustration style. --- ### Phases of Gastric Secretion Gastric acid secretion is divided into three phases based on the location of the stimulus, though all three overlap during a meal. The cephalic phase begins before food reaches the stomach. Sight, smell, taste, and even thought of food activate vagal centers in the medulla. Vagal efferents directly stimulate parietal cells (via acetylcholine) and stimulate G cells to release gastrin. This anticipatory phase contributes approximately 30% of total acid secretion for a meal and prepares the stomach for incoming food. The gastric phase begins when food enters the stomach and produces approximately 60% of total acid secretion. Gastric distension activates mechanoreceptors that trigger vagovagal reflexes and local enteric reflexes, increasing acid output. More importantly, protein digestion products (particularly aromatic amino acids and peptides) directly stimulate G cells in the antrum to release gastrin. Gastrin enters the circulation and returns to the gastric body to stimulate parietal cells and ECL cells. This is the peak period of acid secretion. The intestinal phase occurs when chyme enters the duodenum and accounts for about 10% of total acid secretion. Initially, protein products in the duodenum provide modest stimulation. However, the intestinal phase rapidly becomes inhibitory. Fat in the duodenum triggers CCK release, which inhibits gastric emptying and acid secretion. Acid in the duodenum triggers secretin release, which inhibits gastrin and reduces acid output. Hyperosmolar solutions also trigger inhibitory reflexes. These negative feedback mechanisms protect the duodenum from excessive acid exposure. Local negative feedback operates within the stomach itself. When luminal pH drops below 3, acid directly stimulates D cells to release somatostatin. Somatostatin acts locally to inhibit G cells (reducing gastrin release) and directly inhibits parietal cells. This intrinsic feedback prevents excessive acidification. Panel A: Cephalic phase at 30% showing brain illustration with sensory inputs including sight, smell, and taste icons, vagus nerve descending to stomach, ACh stimulating parietal cells and G cells labeled anticipatory before food arrives. Panel B: Gastric phase at 60% showing food in stomach with distension sensors and protein products stimulating G cells, gastrin circulation loop showing secretion into blood and return to parietal cells labeled peak secretion food in stomach. Panel C: Intestinal phase at 10% showing chyme entering duodenum with early stimulation then inhibition by fat via CCK and acid via secretin with arrows showing inhibitory effects on stomach labeled initially stimulatory then inhibitory. Panel D: Negative feedback showing low gastric pH stimulating D cells to release somatostatin which inhibits both G cells and parietal cells with percentages prominently displayed. --- ### Gastric Mucosal Defense The stomach faces a paradoxical challenge: it must produce highly corrosive acid and pepsin for digestion while protecting itself from damage. Multiple overlapping mechanisms create the gastric mucosal barrier. The mucus-bicarbonate barrier is the first line of defense. Surface mucous cells secrete a continuous layer of mucus gel approximately 0.5 to 1 mm thick. This mucus traps bicarbonate ions secreted by the same cells, creating a pH gradient. While the gastric lumen may have a pH of 1 to 2, the mucus layer at the epithelial surface maintains a pH of 6 to 7. This near-neutral microenvironment protects epithelial cells from acid damage. Epithelial integrity provides additional protection. Tight junctions between surface cells prevent acid from penetrating between cells. If damage occurs, rapid epithelial restitution allows cells to migrate and cover defects within minutes to hours—faster than cell division would allow. Complete epithelial turnover occurs every 3 to 5 days, allowing replacement of any injured cells. Mucosal blood flow is critical for defense. Adequate blood flow delivers bicarbonate to surface cells and removes any hydrogen ions that back-diffuse through the epithelium. When mucosal blood flow is compromised (as in shock), the mucosa becomes vulnerable to acid injury, resulting in stress ulcers. Prostaglandins (particularly PGE2 and PGI2) coordinate multiple protective mechanisms. They stimulate mucus secretion, stimulate bicarbonate secretion, increase mucosal blood flow, and have a minor direct effect decreasing acid secretion. This explains why NSAIDs, which inhibit cyclooxygenase and prostaglandin synthesis, significantly increase ulcer risk. Misoprostol, a prostaglandin analog, can restore mucosal protection in patients requiring chronic NSAID therapy. Helicobacter pylori undermines mucosal defense through multiple mechanisms. Its urease produces ammonia, neutralizing local acid but creating toxic ammonium ions. Various cytotoxins damage epithelial cells. The chronic inflammatory response further injures the mucosa. H. pylori infection underlies most peptic ulcer disease not caused by NSAIDs. Panel A: Mucus-bicarbonate barrier cross-section showing surface epithelium with goblet cells secreting mucus gel layer shown as translucent blue-gray layer, HCO3- molecules trapped in mucus creating pH gradient with pH 1-2 at lumen surface and pH 6-7 at epithelial surface. Panel B: Epithelial defenses showing tight junctions sealing cells with inset showing junction proteins and cell restitution with arrows showing cell migration to cover defect. Panel C: Mucosal blood flow with capillaries beneath epithelium delivering HCO3- and removing back-diffused H+. Panel D: Prostaglandin effects with PGE2 and PGI2 stimulating mucus, bicarbonate, and blood flow while decreasing acid slightly, NSAID shown blocking prostaglandins leading to compromised defense, with inset showing H. pylori with urease, cytotoxins, and inflammation. --- ### Pancreatic Exocrine Secretion The exocrine pancreas secretes a bicarbonate-rich fluid containing the digestive enzymes necessary to process all three macronutrient classes. Two cell types perform distinct functions. Acinar cells clustered in grape-like formations produce and secrete digestive enzymes. Duct cells lining the pancreatic ducts secrete bicarbonate and water. Acinar cells synthesize and store digestive enzymes as inactive precursors (zymogens) in zymogen granules. This packaging protects the pancreas from self-digestion. The protease precursors include trypsinogen, chymotrypsinogen, proelastase, and procarboxypeptidases. These must be activated in the duodenal lumen. Other enzymes are secreted in active form: pancreatic lipase (which requires colipase for optimal function), phospholipase A2 (secreted as a proenzyme activated by trypsin), pancreatic amylase, and nucleases. The enzyme activation cascade begins with enterokinase, a brush border enzyme in the duodenal mucosa. Enterokinase cleaves a small peptide from trypsinogen to produce active trypsin. Trypsin then activates all other pancreatic zymogens, including more trypsinogen (autocatalysis), chymotrypsinogen, proelastase, procarboxypeptidases, and prophospholipase A2. This cascade amplifies the activation signal. Pancreatic secretory trypsin inhibitor (PSTI) in pancreatic juice inactivates any trypsin prematurely activated within the pancreas, protecting against pancreatitis. If this protection fails, premature intrapancreatic enzyme activation causes acute pancreatitis. Duct cells secrete bicarbonate to neutralize gastric acid entering the duodenum. The mechanism involves carbonic anhydrase generating bicarbonate ions, which are secreted through the CFTR chloride channel and a chloride/bicarbonate exchanger on the apical membrane. The CFTR channel secretes chloride, which is immediately exchanged for bicarbonate by the Cl⁻/HCO₃⁻ exchanger. This process can achieve bicarbonate concentrations up to 140 mEq/L, with a correspondingly alkaline pH. In cystic fibrosis, defective CFTR leads to inadequate bicarbonate and water secretion, resulting in thick, protein-rich secretions that obstruct ducts and cause pancreatic insufficiency. Hormonal regulation coordinates enzyme and bicarbonate secretion with nutrient delivery. CCK, released from duodenal I cells by fat and amino acids, is the primary stimulus for acinar cell enzyme secretion. Secretin, released from duodenal S cells by acid, is the primary stimulus for duct cell bicarbonate secretion. Vagal input during the cephalic and gastric phases potentiates the effects of CCK on enzyme secretion. Panel A: Pancreatic anatomy showing acinar cells in grape-like clusters with zymogen granules as dark spots and intercalated ducts leading to larger ducts. Panel B: Acinar cell function with zymogens listed including trypsinogen, chymotrypsinogen, proelastase, and procarboxypeptidases and active enzymes including lipase with colipase and amylase, with activation cascade showing enterokinase converting trypsinogen to trypsin which then activates all other zymogens. Panel C: Duct cell bicarbonate secretion showing CO2 + H2O becoming HCO3- + H+ via carbonic anhydrase, CFTR channel secreting Cl- which is exchanged for HCO3- via Cl-/HCO3- exchanger achieving 140 mEq/L HCO3-. Panel D: Regulation showing CCK from I cells triggered by fat and amino acids stimulating acinar cells and secretin from S cells triggered by acid stimulating duct cells with vagus nerve potentiating CCK effect and PSTI protecting against premature activation. --- ### Bile Secretion and Enterohepatic Circulation Hepatocytes continuously synthesize and secrete bile, a complex fluid essential for fat digestion and cholesterol excretion. The major organic components are bile acids (derived from cholesterol), phospholipids (mainly phosphatidylcholine/lecithin), and cholesterol itself. Bile also contains bilirubin (the end product of heme degradation), electrolytes, and water. Bile acid synthesis begins with cholesterol in hepatocytes. The rate-limiting enzyme is cholesterol 7α-hydroxylase (CYP7A1). The primary bile acids produced in humans are cholic acid and chenodeoxycholic acid. These are conjugated with glycine or taurine to form bile salts, which are more water-soluble and better surfactants. Bile salts are secreted across the canalicular membrane into bile canaliculi. Secondary bile acids form in the intestine through bacterial modification. Colonic bacteria deconjugate and dehydroxylate primary bile acids, producing deoxycholic acid (from cholic acid) and lithocholic acid (from chenodeoxycholic acid). These secondary bile acids are partially reabsorbed and contribute to the circulating pool. The enterohepatic circulation is a remarkably efficient recycling system. Bile acids are secreted into bile and stored in the gallbladder between meals. With eating, CCK triggers gallbladder contraction and sphincter of Oddi relaxation, releasing bile into the duodenum. Bile acids participate in fat digestion throughout the small intestine, forming micelles that deliver lipid digestion products to the brush border. In the terminal ileum, specific bile acid transporters (primarily the apical sodium-dependent bile acid transporter, ASBT) actively reclaim approximately 95% of bile acids. These return to the liver via the portal vein and are re-secreted into bile. The total bile acid pool is only 3 to 4 grams, but it cycles 6 to 10 times daily, meaning 18 to 30 grams of bile acids enter the duodenum each day. The 5% lost in feces (about 0.5 g/day) is replaced by new hepatic synthesis. Bile acid pool size regulates its own synthesis through feedback inhibition. Returning bile acids activate the farnesoid X receptor (FXR) in hepatocytes, which suppresses CYP7A1 expression. If ileal reabsorption is interrupted (by resection, disease, or bile acid sequestrants), the reduced return of bile acids releases this inhibition, dramatically increasing synthesis. Panel A: Hepatocyte bile synthesis showing cholesterol to primary bile acids via 7α-hydroxylase labeled as rate-limiting to cholic acid and chenodeoxycholic acid then conjugation with glycine or taurine to bile salts secreted into canaliculus. Panel B: Bile composition pie chart showing bile acids 67%, phospholipids 22%, cholesterol 4%, bilirubin 0.3%, and other. Panel C: Enterohepatic circulation as circular pathway showing liver secreting bile to gallbladder storing and concentrating 5-10x to CCK triggering release after meal to bile in duodenum forming micelles for fat digestion to 95% reabsorbed in terminal ileum via ASBT transporter to portal vein return to liver to re-secretion with 5% lost in feces replaced by new synthesis with statistics showing pool 3-4g cycling 6-10x/day and 18-30g bile acids delivered daily. Panel D: Bacterial conversion of primary to secondary bile acids in colon with FXR feedback loop shown. --- ### Gallbladder Function The gallbladder performs three key functions: storage of bile during fasting, concentration of bile, and regulated release after meals. Between meals, the sphincter of Oddi maintains tonic contraction, diverting hepatic bile into the gallbladder via the cystic duct. Bile concentration occurs through active sodium absorption by gallbladder epithelium, with water following osmotically. This process concentrates bile 5 to 10-fold, increasing the concentration of bile acids, phospholipids, and cholesterol. The concentrated bile is more efficient at solubilizing dietary fat. Gallbladder contraction is primarily triggered by CCK released from duodenal I cells when fat and protein enter the duodenum. CCK causes smooth muscle contraction of the gallbladder wall while simultaneously relaxing the sphincter of Oddi, allowing concentrated bile to flow into the duodenum. Vagal cholinergic stimulation also contributes to postprandial gallbladder contraction. Cholesterol solubility in bile depends on the relative concentrations of bile acids, phospholipids, and cholesterol. Bile acids and phospholipids form mixed micelles in which cholesterol can be solubilized. If cholesterol concentration exceeds the solubilizing capacity (supersaturation), cholesterol can precipitate as crystals, initiating gallstone formation. Gallstones are classified by composition. Cholesterol stones (70-80% of stones in Western populations) contain predominantly cholesterol and form when bile becomes supersaturated with cholesterol. Risk factors include obesity, female sex, pregnancy, rapid weight loss, and genetic factors (the "5 F's": female, forty, fertile, fat, family history, are classically taught, though this oversimplifies). Pigment stones contain primarily calcium bilirubinate. Black pigment stones form with increased unconjugated bilirubin (as in hemolytic disease or cirrhosis). Brown pigment stones form with bacterial infection and stasis in the biliary tree. Panel A: Gallbladder anatomy between liver lobes with cystic duct connection to common bile duct and sphincter of Oddi. Panel B: Bile concentration process showing gallbladder epithelium actively absorbing Na+ with arrows and water following osmotically with bile concentrated 5-10x showing comparison of dilute hepatic bile entering versus concentrated bile stored. Panel C: Postprandial emptying showing fat and protein in duodenum leading to I cells releasing CCK leading to two effects of gallbladder contraction and sphincter of Oddi relaxation leading to bile entering duodenum. Panel D: Cholesterol solubility diagram with triangular phase diagram with bile acids, phospholipids, and cholesterol at vertices showing micellar zone where cholesterol is soluble and supersaturation zone where crystals form, with gallstone types including cholesterol stones appearing yellow-green and waxy, black pigment stones appearing small and black with hemolysis association, and brown pigment stones appearing brown and soft with infection with risk factors listed for each type. --- ### Intestinal Secretion The intestinal epithelium secretes fluid and mucus while also absorbing nutrients and water. The net balance between secretion and absorption determines whether the intestinal lumen becomes more or less hydrated. Intestinal crypts (crypts of Lieberkühn) are the primary secretory sites. Crypt epithelial cells secrete chloride and water through a mechanism centered on the CFTR chloride channel. The basolateral Na⁺/K⁺/2Cl⁻ cotransporter (NKCC1) brings chloride into the cell, accumulating it above electrochemical equilibrium. When CFTR opens on the apical membrane, chloride flows into the lumen down its electrochemical gradient. Sodium follows paracellularly (between cells) due to the electrical gradient created by chloride movement, and water follows osmotically. This produces an isotonic, chloride-rich secretion. Goblet cells in both crypts and villi secrete mucus, providing lubrication and protection. Paneth cells at the crypt base secrete antimicrobial peptides (defensins) and lysozyme, contributing to innate immune defense. Multiple signals regulate intestinal chloride secretion. VIP (vasoactive intestinal peptide) increases cAMP in crypt cells, activating CFTR and stimulating secretion. Prostaglandins similarly increase cAMP. Acetylcholine increases intracellular calcium, activating alternative chloride channels and promoting secretion. Under normal conditions, these signals fine-tune the fluid content of luminal contents. Secretory diarrhea occurs when secretion overwhelms absorption. The classic example is cholera. Cholera toxin enters intestinal epithelial cells and irreversibly activates the Gs protein that stimulates adenylate cyclase. The resulting massive, sustained increase in cAMP causes continuous CFTR activation and uncontrolled chloride and water secretion. Patients can lose over 10 liters of fluid daily, causing life-threatening dehydration. The heat-labile toxin (LT) of enterotoxigenic E. coli works by the same mechanism. Oral rehydration solution (ORS) exploits the fact that glucose-coupled sodium absorption (via SGLT1) remains functional even when chloride secretion is maximally stimulated. By providing glucose and sodium together, ORS allows continued absorption of sodium and water even as secretion continues, maintaining hydration until the toxin effect subsides. In cystic fibrosis, CFTR dysfunction impairs chloride secretion throughout the body. In the intestine, this causes thickened, dehydrated secretions that can cause meconium ileus in neonates and distal intestinal obstruction syndrome in older patients. Panel A: Crypt anatomy showing intestinal crypts at base of villi with crypt epithelial cells, goblet cells, and Paneth cells at crypt base. Panel B: Chloride secretion mechanism in crypt cell showing basolateral NKCC1 bringing in Na+/K+/2Cl- with Cl- accumulating intracellularly, apical CFTR opening to secrete Cl- into lumen, Na+ following paracellularly between cells, and H2O following osmotically with regulatory signals showing VIP and prostaglandins increasing cAMP leading to CFTR activation and ACh increasing Ca2+ leading to alternative Cl- channels. Panel C: Cholera toxin mechanism showing toxin entering cell leading to irreversible Gs activation leading to greatly increased cAMP leading to continuous CFTR activation leading to massive secretion of 10+ L/day. Panel D: ORS mechanism showing glucose + Na+ entering via SGLT1 which is still functional leading to Na+ and H2O absorption leading to rehydration despite ongoing secretion with CFTR dysfunction in CF noted with thickened secretions. --- ### Clinical Applications Understanding GI secretion informs treatment of common disorders. Acid-related diseases are managed by targeting different steps in acid production. Proton pump inhibitors (PPIs: omeprazole, pantoprazole, esomeprazole) irreversibly bind and inhibit the H⁺/K⁺-ATPase, blocking the final common pathway of acid secretion. They are the most effective acid suppressants and are first-line therapy for GERD, peptic ulcer disease, and H. pylori eradication. H2 receptor antagonists (famotidine, formerly ranitidine) block histamine stimulation of parietal cells, reducing but not eliminating acid secretion. Antacids (calcium carbonate, aluminum/magnesium hydroxide) directly neutralize gastric acid for rapid but temporary relief. Prostaglandin analogs (misoprostol) restore mucosal defense in patients requiring chronic NSAID therapy and can reduce acid secretion. Pancreatic exocrine insufficiency occurs when enzyme output falls below 10% of normal, causing maldigestion. Chronic pancreatitis is the most common cause in adults, followed by cystic fibrosis and pancreatic cancer. Patients develop steatorrhea (fatty stools), weight loss, and deficiencies of fat-soluble vitamins. Treatment involves pancreatic enzyme replacement therapy (PERT)—oral preparations containing lipase, protease, and amylase taken with meals. These are enteric-coated to survive gastric acid and release enzymes in the duodenum. Bile acid disorders include bile acid diarrhea, which occurs when excess bile acids reach the colon (due to ileal resection or dysfunction), stimulating colonic secretion and causing watery diarrhea. Bile acid sequestrants (cholestyramine, colesevelam) bind bile acids in the intestine, preventing their secretory effect. These drugs also lower LDL cholesterol by interrupting enterohepatic circulation and upregulating hepatic LDL receptors. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, can slowly dissolve cholesterol gallstones by reducing biliary cholesterol saturation. Secretory diarrhea management depends on the cause. Oral rehydration remains the cornerstone of therapy for cholera and other enterotoxin-mediated diarrheas. Octreotide, a somatostatin analog, can reduce secretion in VIPomas and some other secretory diarrheas by inhibiting the secretory stimulus. Panel A: Acid suppression with parietal cell showing three drug targets marked including PPI blocking H+/K+-ATPase labeled most effective, H2 blocker blocking histamine receptor, and prostaglandin analog enhancing defense with drug names listed. Panel B: Pancreatic insufficiency with causes listed including chronic pancreatitis, CF, and cancer, symptoms including steatorrhea, weight loss, and fat-soluble vitamin deficiency, and treatment showing enteric-coated PERT capsule releasing enzymes in duodenum. Panel C: Bile acid disorders showing ileal resection leading to bile acids reaching colon leading to secretory diarrhea, bile acid sequestrant binding bile acids, and UDCA reducing cholesterol saturation in gallbladder. Panel D: Secretory diarrhea with ORS solution with glucose and sodium allowing continued absorption via SGLT1 despite toxin-induced secretion and octreotide inhibiting VIP effect in professional clinical illustration style with drug mechanisms clearly shown. --- ## Summary - Salivary secretion: Two-stage model; hypotonic due to duct modification - Gastric acid: H⁺/K⁺-ATPase; stimulated by ACh, gastrin, histamine (potentiation) - Phases: Cephalic (30%), gastric (60%), intestinal (10%) - Mucosal defense: Mucus-bicarbonate barrier, prostaglandins critical - Pancreatic: Secretin → bicarbonate; CCK → enzymes - Bile: Enterohepatic circulation recycles 95% of bile acids - Intestinal: CFTR-mediated Cl⁻ secretion; cholera toxin causes secretory diarrhea --- ## Key Terms | Term | Definition | |------|------------| | Proton pump | H⁺/K⁺-ATPase in parietal cells | | Potentiation | Synergistic effect of acid secretion stimulants | | Enterohepatic circulation | Recycling of bile acids between liver and intestine | | CFTR | Cystic fibrosis transmembrane regulator; Cl⁻ channel | | Secretin | Hormone stimulating pancreatic bicarbonate secretion | | CCK | Hormone stimulating enzyme secretion and gallbladder contraction | | Alkaline tide | Bicarbonate release during acid secretion | | Zymogen | Inactive enzyme precursor | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*